<DOC>
	<DOCNO>NCT02371746</DOCNO>
	<brief_summary>This multiple cohort study evaluate safety efficacy ENV515 travoprost XR patient open-angle glaucoma ocular hypertension .</brief_summary>
	<brief_title>Safety Efficacy ENV515 Travoprost Extended Release ( XR ) Patients With Bilateral Ocular Hypertension Primary Open Angle Glaucoma</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosis either ocular hypertension open angle glaucoma eye . Are currently treat topical PGA ocular hypertension eye . Patients opinion Investigator : IOP eye consider adequately control , safely withdrawn IOP medication eye washout period , consider significant risk disease progression throughout trial . Eye surgery ( include cataract surgery ) within past 3 month . History glaucoma relate surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>